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sTo the Editor: Enteroviral myocarditis is a life-threatening disease
and a frequent cause of terminal heart failure and increased
mortality independently from the severity of left ventricular dys-
function, affecting small children and adolescents even more
frequently than adults (1,2). The course varies from subclinical to
fulminant disease and may insidiously progress to dilated cardio-
myopathy. We previously demonstrated that a 6-month treatment
course with interferon-beta (IFN-) effectively cleared the virus
from the hearts of all treated patients with chronic enteroviral
cardiomyopathy and improved medical conditions significantly (3).
In the short run, spontaneous and treatment-induced virus clear-
ance was associated with clinical and hemodynamic improvement,
while patients with persisting infection slowly deteriorated (3,4).
To gain insight into the long-term effects of IFN- treatment, we
ollowed up the patients from first diagnostic biopsy to as long as
20 months and compared their outcome with treated and un-
reated enterovirus infections.
Only patients with both biopsy-based baseline and follow-up
nformation on the course of the virus infection analyzed by nPCR
ere included in this investigation. We identified 96 patients with
ymptoms of heart failure (for 6 months) including fatigue and
educed physical capacity (69%), dyspnea on exertion (71%),
ngina at rest (36%), or palpitations (38%) and arrhythmias (40%).
ost patients were in New York Heart Association functional
lasses II and III (class II, 54%; class III, 28%; and class IV, 4%).
istological and immunohistological evaluation revealed no sig-
ificant baseline differences between patients with spontaneously
leared and not cleared viral infection (CD3-positive lymphocytes:
 10 cells/mm2 vs. 6  10 cells/mm2, respectively; p  0.61).
The diagnostic procedures have been described earlier (4,5).
The short-term clinical course of 14 consecutive patients treated
with IFN- in a first pilot study, 28 patients with spontaneous
enterovirus clearance, and 28 patients with biopsy-proven virus
persistence have already been reported (3,4). Fourteen of the 28
patients with persisting viral infection could be treated with
IFN-, because the treatment costs were covered by their health
nsurances. The other 14 patients, 7 patients with newly diagnosed
ersisting, and 19 patients with spontaneously cleared infections
ompleted the study group of 96 patients.
The interval between baseline and follow-up biopsy was 9.5 
.6 months for patients who cleared the viral infection (n 47; 29
ale; mean age 47 15 years) and 11.0 7.4 months for patients
with viral persistence (n  49; 33 male; mean age 51  12 years;
p 0.123). All patients received heart failure medication including
angiotensin-converting enzyme inhibitors or angiotensin-receptor
blockers (67%), beta-blockers (65%), spironolactone (45%), and
diuretics (55%), without significant differences among the 3
analyzed cohorts. An implantable cardioverter-defibrillator or
pacemaker was received by 2/0 of IFN-treated patients, 4/1patients with cleared virus, and 3/2 patients with virus persistence,
respectively.
In the interferon treatment group (n  28; 16 male; mean age
48  1 years), the treatment started within 4 months after the
virus-positive follow-up biopsy. Eight million units of IFN- were
administered every other day for 6 months in addition to constant
heart failure medication. The treatment procedure has been
reported earlier (3). Treated patients underwent follow-up biopsy
8.3 2.2 months after the start of the 6 months’ IFN- treatment
ourse.
For the IFN- serum level analysis, venous plasma samples
were obtained by standard venipuncture immediately before the
biopsy procedure and immediately frozen at 80°C. All samples
were analyzed simultaneously in duplicates by commercially avail-
able single-plate enzyme-linked immunosorbent assay kits.
All patients lived in the catchment area of our hospital, enabling
us to obtain long-term information on patients’ outcome. Occur-
rence of the endpoint death was determined through direct contact
with the patient, contact with family members, inquiries at the
registration office, or all 3. Qualitative data were compared by
conducting the chi-square test. Student’s t test was used to analyze
continuous variables. A probability value of a 2-sided p 0.05 was
considered statistically significant. Survival curves were generated
according to the Kaplan-Meier method and were compared with
the log-rank statistic. Patients who did not meet the 10-year
endpoint became censored at the point of their last follow-up. All
analyses were performed using JMP Statistical Discovery Software
7.0 (SAS Institute, Cary, North Carolina).
Patients with persisting virus infection had significantly lower
left ventricular ejection fraction (EF) than patients who cleared the
virus from their myocardium (p  0.003). Patients with sponta-
neous enterovirus elimination confirmed by follow-up biopsy were
significantly less likely to die during a mean follow-up of 91  37
months than were patients with virus persistence (mean follow-up
84.4 45 months). Upon IFN- treatment, all 28 patients cleared
he enteroviral infection from the myocardium. In the long-term
urvival analysis (mean follow-up 95.8  36 months), outcome of
reated patients was considerably improved. As shown in Figure 1A,
he mortality rate was low among patients who spontaneously
leared their cardiac viral infection, whereas 52.5% of patients with
iopsy-proven enterovirus persistence met the endpoint of death.
t 5 years, 92% of patients who had cleared the virus (n  45
EFbaseline 53 16%, EFfollow-up 58 1%], p 0.001) were alive,
n contrast to only 69% of patients with virus persistence (n  12
EFbaseline 39  18%, EFfollow-up 41  16%], p  0.37).
Remarkably, all IFN--treated patients (n  28 [EFbaseline 52 
17%, EFfollow-up 58  14%], p  0.04) were alive at the end of
tudy. Patients with EF45% (n 10) as well as patients with EF
45% (n  18%) achieved long-term benefits from IFN-
treatment.
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October 2, 2012:1295–6Because IFN- cleared the enterovirus infection effectively, we
ompared the serum IFN- levels with the course of the virus
nfection in untreated patients. Serum IFN- levels were signifi-
cantly elevated in patients who cleared the virus spontaneously
(n  47), both in comparison with healthy controls (n  24) and
ith patients having virus persistence (n  28) (Fig. 1B).
Enterovirus persistence is associated with a significantly higher
Figure 1 Mortality Rate in EV-Positive Patientsand Serum IFN- Levels
(A) Mortality rate among patients positive for enterovirus (EV) infection: unad-
justed survival according to virus analysis at follow-up. Spontaneous or drug-
induced enterovirus clearance was associated with a significantly reduced
mortality rate in comparison to patients who had enterovirus persistence
(p  0.0005 by the log-rank test). (B) Serum interferon-beta (IFN-) levels were
significantly elevated in patients who cleared the virus spontaneously. A lack of
IFN- production with low levels as seen in controls was found in all patients
with persisting infection.risk of death for those patients compared with patients capable ofinducing spontaneous virus elimination. Both spontaneous IFN-
production in response to infection and IFN- administered over
6 months were associated with effective enterovirus clearance and
improved outcome. The lack of spontaneous IFN- production
as associated with enterovirus persistence. The precise mecha-
ism by which enterovirus infection affects prognosis, whether by
ltering myocardial function or by inducing arrhythmias, remains a
atter for speculation (5). Our data suggest that administration of
IFN- may favor virus clearance and reduce progression of
virus-induced myocardial injury, with improved long-term survival
as seen in patients with spontaneous virus clearance. This finding
suggests that antiviral treatment should be started in time before
irreversible myocardial damage has developed.
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